Zebrafish Models in Marine Drug Discovery

A special issue of Marine Drugs (ISSN 1660-3397). This special issue belongs to the section "Marine Pharmacology".

Deadline for manuscript submissions: 30 April 2025 | Viewed by 1378

Special Issue Editors


E-Mail Website
Guest Editor
Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China
Interests: marine natural products; cardiovascular activity; zebrafish models; marine phospholipids

E-Mail Website
Guest Editor
Biology Institute, Qilu University of Technology (Shandong Academy of Sciences), Jinan 250103, China
Interests: marine drug; marine sponge; marine sponge symbiotic fungus

Special Issue Information

Dear Colleagues,

Marine organisms are a vital source of lead compounds for drugs. Bioactivity evaluation is an indispensable step in drug discovery. However, evaluating the activity of marine natural products is often limited by their low content.

Zebrafish have the unique advantages of a short reproductive cycle, in vitro embryo development, overall embryo transparency, high genetic similarity to humans, easy maintenance, and low cost. As an ideal vertebrate model, zebrafish are widely used in screening the bioactivity of natural active compounds. Furthermore, activity evaluation using zebrafish models requires minimal sample volumes, making them highly suitable for screening the activity and researching the mechanisms of marine natural products.

For this Special Issue, we invite scientists from both academia and industry to submit articles highlighting the application of zebrafish models in the discovery of active marine natural products and the study of their mechanisms of action.

Dr. Xiaobin Li
Dr. Yun Zhang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • marine drugs
  • zebrafish model
  • active natural product
  • bioactivity screening
  • mechanism of action
  • activity evaluation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

15 pages, 6260 KiB  
Article
Altechromone A Ameliorates Inflammatory Bowel Disease by Inhibiting NF-κB and NLRP3 Pathways
by Lei Li, Jing Huang, Lixin Feng, Liyan Xu, Houwen Lin, Kechun Liu, Xiaobin Li and Rongchun Wang
Mar. Drugs 2024, 22(9), 410; https://doi.org/10.3390/md22090410 - 9 Sep 2024
Viewed by 965
Abstract
Altechromone A, also known as 2,5-dimethyl-7-hydroxychromone, is a hydroxyketone containing one hydroxyl and one ketone group. In this study, we isolated Altechromone A from the marine-derived fungus Penicillium Chrysogenum (XY-14-0-4). Previous reports show that Altechromone A has various activities including tumor suppression, antibacterial, [...] Read more.
Altechromone A, also known as 2,5-dimethyl-7-hydroxychromone, is a hydroxyketone containing one hydroxyl and one ketone group. In this study, we isolated Altechromone A from the marine-derived fungus Penicillium Chrysogenum (XY-14-0-4). Previous reports show that Altechromone A has various activities including tumor suppression, antibacterial, and antiviral activities. However, there is no study about its anti-inflammatory activity in inflammatory bowel disease (IBD). Here, we assess the anti-inflammatory activity, especially in IBD, and its potential mechanism using the zebrafish model. Our results indicated that Altechromone A has anti-inflammatory activity in a CuSO4-, tail-cutting-, and LPS-induced inflammatory model in zebrafish, respectively. In addition, Altechromone A greatly reduced the number of neutrophils, improved intestinal motility and efflux efficiency, alleviated intestinal damage, and reduced reactive oxygen species production in the TNBS-induced IBD zebrafish model. The transcriptomics sequencing and real-time qPCR indicated that Altechromone A inhibited the expression of pro-inflammatory genes including TNF-α, NF-κB, IL-1, IL-1β, IL-6, and NLRP3. Therefore, these data indicate that Altechromone A exhibits therapeutic effects in IBD by inhibiting the inflammatory response. Full article
(This article belongs to the Special Issue Zebrafish Models in Marine Drug Discovery)
Show Figures

Graphical abstract

Back to TopTop